Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2010 1
2011 1
2012 4
2013 5
2014 3
2015 4
2016 2
2017 5
2018 3
2019 2
2020 2
2021 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Multimodal platform for assessing drug distribution and response in clinical trials.
Lopez BGC, Kohale IN, Du Z, Korsunsky I, Abdelmoula WM, Dai Y, Stopka SA, Gaglia G, Randall EC, Regan MS, Basu SS, Clark AR, Marin BM, Mladek AC, Burgenske DM, Agar JN, Supko JG, Grossman SA, Nabors LB, Raychaudhuri S, Ligon KL, Wen PY, Alexander B, Lee EQ, Santagata S, Sarkaria J, White FM, Agar NYR. Lopez BGC, et al. Neuro Oncol. 2022 Jan 5;24(1):64-77. doi: 10.1093/neuonc/noab197. Neuro Oncol. 2022. PMID: 34383057 Free PMC article.
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.
Grossman SA, Romo CG, Rudek MA, Supko J, Fisher J, Nabors LB, Wen PY, Peereboom DM, Ellingson BM, Elmquist W, Barker FG, Kamson D, Sarkaria JN, Timmer W, Bindra RS, Ye X. Grossman SA, et al. Neuro Oncol. 2020 Oct 14;22(10):1422-1424. doi: 10.1093/neuonc/noaa142. Neuro Oncol. 2020. PMID: 32506123 Free PMC article. No abstract available.
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Lee EQ, et al. Neuro Oncol. 2020 May 15;22(5):601-612. doi: 10.1093/neuonc/noaa015. Neuro Oncol. 2020. PMID: 31974566 Free PMC article.
Barriers to accrual and enrollment in brain tumor trials.
Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY. Lee EQ, et al. Neuro Oncol. 2019 Sep 6;21(9):1100-1117. doi: 10.1093/neuonc/noz104. Neuro Oncol. 2019. PMID: 31175826 Free PMC article. Review.
35 results